Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Novo Nordisk A/S ADR (NVO)

Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 219,320,800
  • Shares Outstanding, K 4,465,000
  • Annual Sales, $ 46,792 M
  • Annual Income, $ 15,509 M
  • EBIT $ 19,327 M
  • EBITDA $ 22,656 M
  • 60-Month Beta 0.67
  • Price/Sales 4.71
  • Price/Cash Flow 10.53
  • Price/Book 7.50

Options Overview Details

View History
  • Implied Volatility 45.64% (-0.44%)
  • Historical Volatility 75.05%
  • IV Percentile 46%
  • IV Rank 31.78%
  • IV High 70.99% on 04/08/25
  • IV Low 33.83% on 02/12/25
  • Expected Move (DTE 2) 1.44 (2.95%)
  • Put/Call Vol Ratio 0.57
  • Today's Volume 26,687
  • Volume Avg (30-Day) 137,204
  • Put/Call OI Ratio 0.84
  • Today's Open Interest 1,520,168
  • Open Int (30-Day) 1,466,762
  • Expected Range 47.30 to 50.18

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 0.88
  • Number of Estimates 3
  • High Estimate 0.99
  • Low Estimate 0.78
  • Prior Year 0.92
  • Growth Rate Est. (year over year) -4.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
43.24 +12.72%
on 02/05/26
64.16 -24.03%
on 01/23/26
-10.07 (-17.12%)
since 01/09/26
3-Month
43.08 +13.14%
on 11/24/25
64.16 -24.03%
on 01/23/26
-0.41 (-0.83%)
since 11/11/25
52-Week
43.08 +13.14%
on 11/24/25
93.80 -48.04%
on 02/25/25
-35.00 (-41.80%)
since 02/11/25

Most Recent Stories

More News
As Hims & Hers Gets Hit With Major Wegovy Loss, Should You Buy the Dip in Deeply Oversold HIMS Stock?

Hims & Hers shares crater as Novo Nordisk files a lawsuit against the telehealth firm. BofA analysts see significant further downside in HIMS stock.

HIMS : 16.69 (-3.19%)
NVO : 48.74 (-0.77%)
Eli Lilly Booms, Then Busts: Stellar Guidance vs Hims Undercut

Investors had little time to celebrate Eli Lilly's huge post-earnings gain. While Hims & Hers Health knocked shares down, LLY remains a healthcare stalwart.

HIMS : 16.69 (-3.19%)
NVO : 48.74 (-0.77%)
JNJ : 240.86 (+1.05%)
LLY : 1,015.21 (-0.96%)
Unusual Options Activity Alert: 3 Stocks Setting Up for Major Profit Potential

Volatility returned to markets yesterday, triggering a tech rout. Among the unusually active options on Thursday were 278 calls and puts with Vol/OI ratios of 15 or higher. Among them, these 3 stocks offer...

MSTR : 126.07 (-5.21%)
VFC : 20.81 (-0.48%)
QCOM : 141.04 (+0.68%)
ETSY : 47.46 (-12.24%)
LOGI : 93.32 (+1.00%)
NVO : 48.74 (-0.77%)
LLY : 1,015.21 (-0.96%)
PFE : 27.73 (+0.43%)
The Metabolic Split: Why Eli Lilly Soars as Novo Stumbles

Eli Lilly surges past the trillion-dollar mark as aggressive manufacturing expansion drives volume growth that eclipses rival Novo Nordisk in 2026.

NVO : 48.74 (-0.77%)
LLY : 1,015.21 (-0.96%)
As Novo Nordisk Stock Breaks Below Key Support Levels, Should You Buy the Dip?

Novo Nordisk stock sank as management forecasts decelerating growth in 2026. But should you treat this selloff in NVO shares as a buying opportunity? Let’s find out.

NVO : 48.74 (-0.77%)
LLY : 1,015.21 (-0.96%)
Commodity Volatility, Earnings and Other Key Things to Watch

Markets enter February following a volatile final trading day of January that saw investors grappling with hotter-than-expected inflation data alongside news of a new Federal Reserve chair nominee.

PYPL : 40.46 (-2.48%)
MSTR : 126.07 (-5.21%)
GOOGL : 310.96 (-2.39%)
NVO : 48.74 (-0.77%)
MRK : 119.31 (+1.84%)
PFE : 27.73 (+0.43%)
DIS : 108.12 (-1.67%)
QCOM : 141.04 (+0.68%)
LLY : 1,015.21 (-0.96%)
AMD : 213.58 (unch)
RBLX : 68.99 (-4.10%)
ARM : 125.28 (-0.53%)
The New Wegovy Pill Is Already Popular. Does That Make Novo Nordisk Stock a Buy for Q1?

Novo Nordisk entered 2026 with fresh momentum after the U.S. launch of its oral Wegovy pill. Is the stock a buy now?

NVO : 48.74 (-0.77%)
JPM : 310.82 (-2.34%)
LLY : 1,015.21 (-0.96%)
Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All

As weight loss drugs move from injections to pills, this thematic ETF provides broad exposure for investors looking to profit from the industry’s next leg up.

VKTX : 28.55 (-0.70%)
AZN : 204.76 (+5.87%)
OZEM : 35.60 (-0.01%)
NVO : 48.74 (-0.77%)
LLY : 1,015.21 (-0.96%)
REGN : 778.97 (+3.19%)
AMGN : 366.58 (+0.53%)
PFE : 27.73 (+0.43%)
Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns

After tanking on Novo's "Wegovy Pill" release, Eli Lilly shares reversed course. See why investors may like its acquisition of Ventyx Biosciences.

VTYX : 13.94 (-0.14%)
NVO : 48.74 (-0.77%)
LLY : 1,015.21 (-0.96%)
This ETF Is Proof That the Healthcare Rebound Is Real

Track healthcare’s 2026 setup: GLP-1 drug adoption, a valuation gap vs. tech, and why VHT offers broad exposure with low fees and dividends.

CVS : 77.02 (+1.74%)
VHT : 288.78 (+0.42%)
NVO : 48.74 (-0.77%)
JNJ : 240.86 (+1.05%)
MRK : 119.31 (+1.84%)
HCA : 531.47 (+5.86%)
ABBV : 220.89 (-0.70%)
UNH : 278.91 (+2.08%)
ELV : 330.25 (+1.42%)
PFE : 27.73 (+0.43%)
TSLA : 428.27 (+0.72%)
LLY : 1,015.21 (-0.96%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care...

See More

Key Turning Points

3rd Resistance Point 49.99
2nd Resistance Point 49.47
1st Resistance Point 49.11
Last Price 48.74
1st Support Level 48.23
2nd Support Level 47.71
3rd Support Level 47.35

See More

52-Week High 93.80
Fibonacci 61.8% 74.42
Fibonacci 50% 68.44
Fibonacci 38.2% 62.46
Last Price 48.74
52-Week Low 43.08

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar